Bright Green Responds to False Claims Made Against the Company
GRANTS, N.M., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced refutation of allegations made public by Mr. Jerry Capussi and Mr. John Fikany. The Company remains focused on continued execution of its business plan and is awaiting full approval from the U.S. Drug Enforcement Administration (DEA).
- The Company remains focused on continued execution of its business plan and is awaiting full approval from the U.S. Drug Enforcement Administration (DEA).
- Bright Green refutes the claims made by Mr. Capussi and Mr. Fikany, specifically:
Mr. Fikany has never been, nor offered the role, of Chief Executive Officer of Bright Green Corporation. - Bright Green has been and remains fully compliant in both its listing on the Nasdaq and its Securities and Exchange Commission (SEC) reporting before and following the listing.
- Further details on the Bright Green EB-5 program can be found by visiting our dedicated EB-5 website: https://bgxxeb5fast.com/ .